Ardelyx drug reduces elevated phosphate levels Analysts, Chronic Kidney Disease, Clinical Trials, Dialysis, Elevated blood phosphate levels, FDA, Phosphate binders, Phosphate lowering, Phosphates, R&D, Shares Ardelyx Inc.’s experimental medicine tenapanor showed promise in a late-stage study as a standalone therapy to reduce elevated blood phosphate levels in patients with chronic kidney disease (CKD). Read more December 3, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-12-03 07:49:122019-12-03 13:01:00Ardelyx drug reduces elevated phosphate levels
